Glaukos (GKOS) vs ResMed (RMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Glaukos (GKOS) has outperformed ResMed (RMD) over the past year, gaining 104.8% versus a loss of 20.2%. Over five years, GKOS leads with a +284.2% price change compared with -11.6% for RMD. ResMed is the larger company by market cap ($31.56 billion vs $8.76 billion), about 3.6 times the size, while Glaukos is growing revenue faster (+32.3% vs +9.9%).
On valuation, ResMed trades at a lower forward P/E (17.0x vs 283.6x for Glaukos). ResMed pays a dividend yielding 1.07%, while Glaukos does not currently pay one. ResMed converts more of its revenue into profit, with a net margin of 26.9% versus -37.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GKOS | RMD |
|---|---|---|
| Share price | $148.49 | $224.40 |
| Market cap | $8.76B | $31.56B |
| 1-day change | -13.76% | -0.70% |
| YTD return | +52.49% | -6.18% |
| 1-year return | +104.76% | -20.23% |
| 5-year return | +284.16% | -11.55% |
| P/E ratio (TTM) | — | 21.51 |
| Forward P/E | 283.61 | 16.96 |
| EPS (TTM) | $-3.26 | $10.43 |
| Dividend yield | 0.00% | 1.07% |
| Annual dividend | $0.00 | $2.40 |
| Revenue (latest FY) | $507.44M | $5.65B |
| Revenue growth (YoY) | +32.33% | +9.85% |
| Net income (latest FY) | $-187.69M | $1.52B |
| Gross margin | 55.72% | 61.06% |
| Operating margin | -39.33% | 33.37% |
| Net margin | -36.99% | 26.94% |
| 52-week high | $191.62 | $284.05 |
| 52-week low | $73.16 | $180.27 |
| Distance from 52-week high | -22.51% | -21.00% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +33.81% | +11.51% |
| Average volume | 798.61K | 1.34M |
| Shares outstanding | 58.98M | 140.64M |
| Employees | 1,094 | 11,370 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ResMed is about 3.6 times larger than Glaukos by market value ($31.56B vs $8.76B).
- GKOS has outperformed RMD by 125.0 percentage points over the past year.
- ResMed offers a meaningfully higher dividend yield (1.07% vs 0.00%).
- ResMed is more profitable, keeping 26.9 cents of every revenue dollar as net income versus -37.0 cents for Glaukos.
- Glaukos grew revenue faster in its latest fiscal year (+32.33% vs +9.85%).
About Glaukos
GKOS stock →Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.
Health Care · Medical/Dental Instruments · 1,094 employees
About ResMed
RMD stock →ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally.
Health Care · Medical/Dental Instruments · 11,370 employees
GKOS vs RMD FAQ
Which is bigger, Glaukos or ResMed?
ResMed (RMD) is larger, with a market capitalization of $31.56B compared with $8.76B for Glaukos (GKOS).
Which stock has performed better over the past year, GKOS or RMD?
GKOS returned +104.76% over the past 12 months, compared with -20.23% for RMD (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Glaukos or ResMed?
ResMed pays a dividend yielding 1.07%, while Glaukos does not currently pay a regular dividend.
Are Glaukos and ResMed in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.